Tag: closing price

SAN CARLOS, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL”) therapies for patients with cancer, today announced that on July 17, 2025 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 138,190 shares of Iovance’s common stock to 20 new, non-executive employees.

CAMBRIDGE, Mass., July 18, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, effective as of July 17, 2025, the Compensation Committee of the Board of Directors granted Qing Zuraw, M.D., the Company’s Chief Development Officer, 4,373,040 stock options and 937,080 restricted stock units (“RSUs”) in connection with the commencement of her employment. The foregoing stock option and RSU awards were granted as a material inducement to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).

SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 16, 2025 it granted stock options to purchase an aggregate of 131,683 shares of common stock and 88,755 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 18 employees, whose employment commenced in June and July 2025 as a material inducement to their employment.

CONSHOHOCKEN, Pa., July 16, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on July 1, 2025 and July 15, 2025 to a total of 30 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

NEW YORK and NEW ORLEANS, July 15, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 12, 2025 to file lead plaintiff applications in a securities class action lawsuit against Tempus AI, Inc. (NasdaqGS: TEM), if they purchased the Company’s shares between August 6, 2024 and May 27, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.

Tel-Aviv, Israel, July 14, 2025 (GLOBE NEWSWIRE) -- Ellomay Capital Ltd. (NYSE American; TASE: ELLO) (“Ellomay” or the “Company”), a renewable energy and power generator and developer of renewable energy and power projects in Europe, USA and Israel, today announced that it received and accepted, following the approval of its Board of Directors, commitments from several Israeli institutional and classified investors to buy 926,000 ordinary shares of the Company in a private placement (the “Private Placement”). As a result of the Private Placement, an affiliate of Menora Mivtachim Holdings Ltd. (one of Israel’s largest institutional investors), which holds securities for the benefit of members of provident funds or pension funds, is expected to become an interested party in the Company, holding approximately 6% of the Company’s outstanding shares.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In UnitedHealth (UNH), Bitfarms (BITF), or Reddit (RDDT) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vestis (VSTS), PepGen (PEPG), Reckitt (RBGLY), or Tempus (TEM) To Contact Him Directly To Discuss Their Options

NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, has filed a securities class action lawsuit in the United States District Court for the Southern District of California against XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP (“XPLR” or the “Company”) (NYSE: XIFR), and certain of its former and current officers and/or directors (collectively, “Defendants”). The Class Action asserts claims under §§10(b) and 20(a) of the Securities Exchange Act of 1934 (15 U.S.C. §§78j(b) and 78t(a)) and U.S. Securities and Exchange Commission Rule 10b-5 promulgated thereunder (17 C.F.R. §240.10b 5) on behalf of all persons other than Defendants who purchased or otherwise acquired XPLR common units between September 27, 2023 and January 27, 2025, inclusive (the “Class Period”), and were damaged thereby (the “Class”). The Class Action filed by Scott+Scott is captioned: James Alvrus v. XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP, et al., Case No. 3:25-cv-01755.